PHM Share Price | Pharma Mar SA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

184.91 k

Shareholding (Mar 2024)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

Compare Pharma Mar SA with Similar Stocks

Naturhouse Health SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Negative results for the last 3 consecutive quarters

OPERATING CF(Y) Lowest at EUR -13.45 MM
ROCE(HY) Lowest at -10.90 %
INVENTORY TURNOVER RATIO(HY) Lowest at 3.73 times

With ROE of 29.79%, it has a Very Expensive valuation with a 5.63 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 1,576 Million ()

P/E

19.00

Industry P/E

Dividend Yield

7.76%

Debt Equity

-0.64

Return on Equity

29.79%

Price to Book

6.26

Revenue and Profits:

Net Sales:

90 Million

(Quarterly Results - Dec 2025)

Net Profit:

60 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

15.11%

6 Months

2.14%

1 Year

8.07%

2 Years

209.35%

3 Years

96.42%

4 Years

31.08%

5 Years

-10.85%

Pharma Mar SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-2.05%

EBIT Growth (5y)

-21.81%

EBIT to Interest (avg)

10.01

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

0.93

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

18.83%

Pledged Shares

Institutional Holding

ROCE (avg)

68.10%

ROE (avg)

279.38%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.63

EV to EBIT

32.24

EV to EBITDA

26.89

EV to Capital Employed

9.77

EV to Sales

5.87

PEG Ratio

0.10

Dividend Yield

8.63%

ROCE (Latest)

30.31%

ROE (Latest)

29.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 86.98% vs 19.51% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 219.25% vs 375.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "90.50",
          "val2": "48.40",
          "chgp": "86.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "42.30",
          "val2": "5.20",
          "chgp": "713.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "59.70",
          "val2": "18.70",
          "chgp": "219.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "445.30%",
          "val2": "64.00%",
          "chgp": "38.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 26.59% vs 10.56% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 187.36% vs 2,272.73% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "221.40",
          "val2": "174.90",
          "chgp": "26.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "48.30",
          "val2": "9.30",
          "chgp": "419.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "2.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "0.20",
          "chgp": "500.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "75.00",
          "val2": "26.10",
          "chgp": "187.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "181.90%",
          "val2": "14.70%",
          "chgp": "16.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

90.50

48.40

86.98%

Operating Profit (PBDIT) excl Other Income

42.30

5.20

713.46%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

59.70

18.70

219.25%

Operating Profit Margin (Excl OI)

445.30%

64.00%

38.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 86.98% vs 19.51% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 219.25% vs 375.00% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

221.40

174.90

26.59%

Operating Profit (PBDIT) excl Other Income

48.30

9.30

419.35%

Interest

2.50

Exceptional Items

1.20

0.20

500.00%

Consolidate Net Profit

75.00

26.10

187.36%

Operating Profit Margin (Excl OI)

181.90%

14.70%

16.72%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 26.59% vs 10.56% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 187.36% vs 2,272.73% in Dec 2024

All Annual Results

Company CV

About Pharma Mar SA

Pharma Mar SA

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available